Novo Nordisk A/S Common Stock (NVO)

These two have been neglected by Wall Street too much.

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a

This pharma giant is entering the rapidly expanding market for weight loss drugs.

While Novo Nordisk has been victimized by broader market pressure, NVO stock has just flashed a reliable quant signal for bullish traders.

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending.

Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from retail traders.

Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move orchestrated by its top investor, the non-profit Novo Nordisk Foundation. The shake-up, which will see seven independent board members, including the chairman, step

The rapid growth rates of recent years aren't guaranteed to continue.

Don't try to catch a falling surgical knife.

The tides continue to change in Eli Lilly's favor in the GLP-1 space.

That's plenty of time for these drugmakers to move past their challenges.

These companies are jockeying for position in a potential $150 billion market opportunity.

Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday.

Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.

Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs.

The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of